AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of ...

AstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals. The British-Swedish pharma giant on Tuesday said ...

AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...

Key Takeaways A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial ...

(Sharecast News) - AstraZeneca updated the market on two ongoing drug trials on Monday, with a key trial in breast cancer failing to improve survival. The FTSE 100 pharmaceutical giant said the ...

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.

AstraZeneca breast cancer drug trial fails to extend lives of patients. Britain's largest pharma firm said drug did not 'achieve statistical significance' ...

AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...